AI FOR HEOR & MARKET ACCESS

Prepare reimbursementsubmissions faster.

AI drafts HTA submissions, pricing briefs, and payer responses from your existing evidence—with sources attached for expert review.

For HEOR, HTA, Pricing & Global Market Access teams.
Early-access pilots · Platform in development

01 / Your existing evidence
Clinical evidencePDF
Value dossiersDOCX
Economic modelsXLSX
02 / Drafts for your reviewers
HTA submission sections
Pricing decision briefs
Assessor responses
01 / Keep access work on schedule

Keep reimbursement work
on schedule.

Draft the dossier, prepare local versions, and answer evidence questions from the same source documents.

ODYSSEY / GLOBAL VALUE DOSSIERSYNTHETIC EXAMPLE

Get the global dossier ready sooner.

AI drafts your value dossier from study reports and literature, with supporting sources attached for review.

Example Draft the comparative-efficacy section from the study report, keeping the comparator, population, and follow-up explicit.

Draft claimSupporting evidenceStatus

You provide

Study reports, published evidence, and your dossier template.

You receive

Draft value-dossier sections, payer narratives, and source links.

Measure the change

Days to internal sign-off; total drafting and review hours.

Synthetic examples. Pilot scope and expert review are agreed in advance. JCA clinical work, national economic work, and new analyses are scoped separately.

02 / Reduce avoidable review work

Catch errors
before submission.

Check claims, figures, and references across the dossier, model documentation, and payer materials before final sign-off.

01

Find conflicting figures.

Compare patient counts, data cuts, currencies, and assumptions across documents.

02

Check what supports each claim.

Open the source passage behind a claim and flag missing support.

03

Focus review on changed sections.

See which claims and sections need review when an input changes.

CROSS-DOCUMENT CHECK / 001REVIEW REQUIRED
Issue identified

The dossier and model use different eligible populations.

Dossier § 3.1 ↔ Model inputs · Row 12
SUPPORTING DETAIL
Synthetic example / Population definition

The dossier defines adults after one prior line of therapy. The model’s input sheet includes the broader indicated population.

ACTION: RECONCILE DEFINITIONSOWNER: HEOR LEAD

ILLUSTRATIVE EXAMPLE · NOT CLINICAL EVIDENCE

03 / Test it on your next deliverable

Measure the
time saved.

Start with one dossier section, market adaptation, pricing brief, or assessor response and compare time to sign-off with your current process.

01Choose the deliverable and deadline.
02Agree the source material, review criteria, and pilot fee.
03Compare elapsed days, total team hours, and corrections.

Get your next deliverable moving.

Tell us what is due and when.

Please do not submit patient data or confidential asset information.

Start with the evidence you already have.

Use your existing evidence.

Start with your study reports, dossiers, templates, and model outputs; we agree an editable deliverable and review criteria before work starts.

Keep your experts in control.

Your team approves methods, interpretation, model outputs, and final wording; new analyses, model development, and regulatory submission publishing are separate scopes.

Start with a scoped pilot.

The platform is in development, and we are scoping AI-enabled service pilots with agreed outputs, review responsibilities, timing, and fees.

Discuss the work before sharing files.

Initial scoping can use public or synthetic material; confidential documents require an agreed contract and data-handling review.

Prepare your next submissionScope a pilot

Review before sign-off.

Pilot acceptance criteria

Define the task. Agree the source versions, deliverable, reviewer, and acceptance criteria before the pilot.

Check the evidence. Review whether each source supports the claim; distinguish sourced facts, model outputs, and assumptions.

Measure the result. Compare elapsed days to internal acceptance and total preparation plus review hours, alongside material corrections and unresolved issues.

Workflow benefits are proposed pilot objectives, not measured performance. Approval, pricing, and reimbursement outcomes are not guaranteed.